India Pediatric Drugs And Vaccines Market Future Outlook To 2021: Ken Research

1
India Pediatric Drugs And Vaccines Market Future
Outlook To 2021 Ken Research
2
How the Pediatric Drugs and Vaccines Market is
Positioned in India? India, a home of the largest
pediatric population of the world and also has
the highest number of annual child births in the
world. However, almost 80-90 of the drugs used
in children presently have never been studied for
their efficacy in pediatric population. In India,
results of the studies conducted in adult
population are extrapolated for use in children.
There are no specific medicine development
regulations for pediatrics. Indian clinical
practice relies heavily upon safety and efficacy
data published in other developed countries or on
inference from adult dosing.
3
India pediatric drugs and vaccine market has
witnessed tremendous growth in the last five
years largely due to high number of annual births
recorded at around million, launch of generic
formulations of several pediatric drugs including
flavored TB drugs, inclusion of several vaccines
in the national immunization schedule of the
country and inclining coverage of children
vaccination under national immunization schedule.
The market for pediatric drugs and vaccine in
India has been dominated by pediatric drugs,
driven by the availability of large portfolio of
drugs for treatment of several diseases as
compared to a limited number of vaccines for
prevention of some infectious diseases. High
efficacy of vaccines has ensured prevention
against diseases by virtue of few doses of
vaccines. On the other hand, repeated incidence
of some or the other non-vaccine preventable
medical conditions coupled with comparatively
heavy requirement of drug doses have resulted in
a far greater usage of drugs. India pediatric
drugs and vaccine market has grown at an
overwhelming pace in the last five years,
exhibiting growth at a CAGR of during the
period FY2011 to FY2016 from INR billion in
FY2011 to INR billion in FY2016.
4

• How has the Pediatric Drugs Segment Performed?
• About of child mortality is registered in the
  country. Respiratory diseases including pneumonia
  and tuberculosis are other commonly treatable
  conditions for which drugs find extensive usage
  in the country. Nearly million children are
  reported to die due to pneumonia every year.
  Owing to less prevalence of lifestyle diseases
  amongst pediatric population, market share of
  drugs meant for management of diseases has been
  low. Drug meant for management of diseases are
  typically chronic diseases, particularly
  degenerative non-communicable diseases (NCDs)
  such as chronic respiratory diseases,
  cardiovascular diseases, cancer, HIV/AIDS and
  diabetes amongst others.
• Anti-infectives were the most frequently
  prescribed drug class by pediatricians, with over
  of the prescriptions had some form of
  prescribed antibiotics. This is due to the wide
  scale prevalence of children being affected by
  respiratory diseases or some sort of microbial
  infections at regular basis. Anti-histamines are
  drugs used for the treatment of allergies.

5

• Owing to high occurrence of allergies amongst
  children, anti-histamines are next best selling
  drug class. Commonly prescribed anti-histamines
  include chlorphenamine, dexamethasone,
  epinephrine, hydrocortisone and prednisolone. In
  India, about of children aged between 5-11
  years are known to suffer from asthma and the
  prevalence is expected to rise further with
  growing industrialization and changing
  biodiversity.
• What is the Scenario of the Pediatric Vaccines
  Segment?
• India has emerged as the leading vaccine producer
  in the world, in terms of doses of vaccines
  produced, and has about major vaccine
  manufacturing facilities across the country.
  Vaccines manufactured in these facilities are
  offered in both national and international market
  (over 150 countries). With over million births
  every year, the domestic market for vaccines in
  India is huge. The country has been self
  sufficient in meeting the domestic needs, with
  private sector responsible for providing a large
  part of the supply needs. However, India lacks in
  coverage rate of basic vaccines. The Indian
  domestic market for Universal Immunization
  Programme (UIP) alone is over million doses.

6
The RD cost of UIP vaccines is minimal however,
the non-UIP vaccines involve technology
licensing, RD, infrastructure and operational
costs. In addition, stringent regulatory
requirements for the licensing of newer vaccines,
add up to the cost. More than of all measles
vaccines used globally are produced in India.
Moreover, Indian firms are big suppliers to the
UN agencies, accounting in between and of
the vaccines purchased by organization every
year. India has emerged as a major vaccine
producer in recent times by focusing on
geographical regions where vaccines are not
funded by the UN or charitable organizations and
strategic ties with UN and government agencies to
supply vaccines at affordable prices. The Indian
pediatric market for vaccines has grown at a
remarkable CAGR of during the period
FY2011-FY2016.
7
The growth was attributed to some crucial
vaccines (polio, hepatitis B, MMR and BCG)
manufactured by Indian companies constantly
featured in WHOs prequalified list coupled with
the fact that Indian companies (Serum Institute
of India, Bharat Biotech, Panacea Biotec) acted
as major suppliers of vaccines to WHO, UNICEF,
PATH and other UN agencies. The market for
pediatric vaccines grew from INR billion in
FY2011 to INR billion in FY2016. Companies
Cited in the Report List of Major Companies
Companies Covered in the
Report Sun Pharmaceuticals Lupin
Pharmaceuticals Cipla Dr. Reddys Laboratories
Major Players Abbott
India Serum Institute of India Panacea Biotec
8

• Bharat Biotech
• GSK Pharmaceuticals
• Biological E Limited
• Key Factors Considered in the Report
• Comprehensive analysis of the India pediatric
  drugs and vaccines market and its segments
• Listed major players and their offerings
• Identified major developments in last few years
  and assessed the future growth of the industry
• Government initiatives taken to stimulate the
  growth of the market.
• For more coverage click on the link below
• https//www.kenresearch.com/healthcare/pharmaceuti
  cals/india-pediatric-drug-vaccine-market/81319-91.
  html

9
Contact UsKen ResearchAnkur Gupta, Head
Marketing CommunicationsAnkur_at_kenresearch.com
91-9015378249